In Vivo is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Bayer AG

www.bayer.com

Latest From Bayer AG

Korea IND Filing Moves Alteogen's Eylea Biosimilar Forward

South Korean biotech Alteogen is progressing the development of its Eylea biosimilar both at home and abroad, with the hope of becoming a global first mover with its version in wet AMD, backed by formulation and manufacturing patents.

South Korea Biosimilars

Could New Governments In Brazil, Mexico Derail International Regulatory Convergence?

Bayer's Patrick Brady says nationalist sentiments raise concerns, but he remains hopeful that technology and progress will continue to drive globalization.
Regulation Policy

Sanofi Clarifies Xyzal-Zyrtec Size Comparison, Outweighs J&J Calculation

National Advertising Division recommends Sanofi add "nearly" to claim that Xyzal Allergy 24HR is "as effective at half the size" of J&J's Zyrtec in a TV ad because 3D modeling comparing the products showed Xyzal tablet has 73-mm volume and a Zyrtec tablet's is 145.2 mm. Sanofi's evidence also supported referring to Xyzal's size would not mislead consumers to expect its drug has half the pharmaceutical dosage of Zyrtec.

France Germany

Merck's Keytruda Loss In Liver Cancer Could Be Gain For Rivals

The drug demonstrates improvements in overall survival and progression-free survival, but not enough for success in KEYNOTE-240.

Clinical Trials Research & Development
See All

Company Information

Advertisement
Advertisement
UsernamePublicRestriction

Register